Overview

Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control

Status:
Withdrawn
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.
Phase:
Phase 3
Details
Lead Sponsor:
EMS
Treatments:
Candesartan
Candesartan cilexetil
Chlorthalidone
Hydrochlorothiazide
Losartan